TABLE 3.
Baseline genotypic analysis of RSV F gene
| Subject group | No. (%) of subjects in study populationa |
||||
|---|---|---|---|---|---|
| HCT URTI (GS-US-218-0108) | HCT LRTI (GS-US-218-1502) | Lung transplant (GS-US-218-1797) | Hospitalized patients (GS-US-218-1227) | All | |
| Presatovir-treated subjects | 89 | 29 | 35 | 80 | 233 |
| With baseline F sequence data | 89 (100) | 28 (96.6) | 33 (94.3) | 76 (95.0) | 226 (97.0) |
| With any substitutions at resistance positionsb | 3 (3.4) | 1 (3.4) | 1 (2.9) | 0 | 5 (2.1) |
| With V127A | 3 (3.4) | 1 (3.4) | 1 (2.9) | 0 | 5 (2.1) |
| Placebo-treated subjects | 87 | 28 | 19 | 74 | 208 |
| With baseline F sequence data | 44 (50.6) | 26 (92.9) | 19 (100) | 58 (78.4) | 147 (70.7) |
| With any substitutions at resistance positions | 2 (2.3) | 1 (3.6) | 0 | 0 | 3 (1.4) |
| With V127A | 2 (2.3) | 1 (3.6) | 0 | 0 | 3 (1.4) |
a
HCT, hematopoietic cell transplant; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection.
b
Resistance substitutions are listed in Table 2.